Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.02 USD | +7.47% | +8.05% | -5.03% |
03-07 | Lumos Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
03-07 | Transcript : Lumos Pharma, Inc., 2023 Earnings Call, Mar 07, 2024 |
Sales 2024 * | 8.81M 12.1M | Sales 2025 * | 8.64M 11.86M | Capitalization | 24.51M 33.66M |
---|---|---|---|---|---|
Net income 2024 * | -35M -48.06M | Net income 2025 * | -39M -53.55M | EV / Sales 2024 * | 2.78 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 2.84 x |
P/E ratio 2024 * |
-1.07
x | P/E ratio 2025 * |
-1.51
x | Employees | 33 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 64.98% |
Latest transcript on Lumos Pharma, Inc.
1 day | +7.47% | ||
1 week | +8.05% | ||
Current month | +7.47% | ||
1 month | +6.34% | ||
3 months | +0.33% | ||
6 months | -16.11% | ||
Current year | -5.03% |
Managers | Title | Age | Since |
---|---|---|---|
Richard Hawkins
CEO | Chief Executive Officer | 75 | 10-08-31 |
Lori Lawley
DFI | Director of Finance/CFO | 40 | 20-02-29 |
John McKew
PSD | President | 59 | 15-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Lota Zoth
BRD | Director/Board Member | 64 | 12-10-31 |
Richard Hawkins
CEO | Chief Executive Officer | 75 | 10-08-31 |
Kevin Lalande
BRD | Director/Board Member | 51 | 13-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-01 | 3.02 | +7.47% | 278,286 |
24-04-30 | 2.81 | -0.71% | 19,747 |
24-04-29 | 2.83 | +2.17% | 13,699 |
24-04-26 | 2.77 | +0.36% | 688 |
24-04-25 | 2.76 | -1.25% | 1,569 |
Delayed Quote Nasdaq, May 01, 2024 at 04:30 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-5.03% | 22.81M | |
+0.67% | 42.19B | |
+44.30% | 40.15B | |
-6.20% | 28.31B | |
+6.55% | 24.63B | |
-21.66% | 18.2B | |
+29.96% | 12.01B | |
-1.57% | 11.76B | |
+16.03% | 10.4B | |
-4.80% | 9.94B |
- Stock Market
- Equities
- LUMO Stock